Mental Health

  • For opioid-related hospitalizations, men and women are equal

    on June 22nd, 2017
    Equality is not always a good thing, particularly with opioids. In 2005, the rate of opioid-related inpatient hospital stays was 145.6 per 100,000 population for males of all ages and 127.8 for females of all ages. By 2014, however, equality had arrived: Females had a rate of 224.1 per 100,000, comp[...]
  • Arab Americans reluctant to seek depression care from psychiatrists

    on June 22nd, 2017
    EXPERT ANALYSIS FROM APA SAN DIEGO (FRONTLINE MEDICAL NEWS) – A new study, the first of its kind, finds that Arab Americans in a Michigan community are among least likely ethnic groups to seek help for depression from a mental health specialist. But they’re especially likely to look for assistan[...]
  • Weekly buprenorphine depot effective for opioid use disorder

    on June 22nd, 2017
    FROM JAMA Psychiatry A weekly subcutaneous buprenorphine depot could improve adherence and reduce the potential for misuse, according to a study presented at the annual meeting of the College on Problems of Drug Dependence and published simultaneously June 22 in JAMA Psychiatry. In a phase II, doubl[...]
  • Mydayis approved for teens, adults with ADHD

    on June 22nd, 2017
    The Food and Drug Administration has approved a once-a-day treatment for patients aged 13 years and older with ADHD, Shire announced June 20 in a press release. The approval of Mydayis was based on results from 16 clinical studies evaluating the medication in more than 1,600 adolescents (aged 13-17 [...]
  • Cotempla XR-ODT approved for children, adolescents with ADHD

    on June 21st, 2017
    The Food and Drug Administration has approved the first methylphenidate extended-release orally disintegrating tablet for treating ADHD in patients aged 6-17 years old, Neos Therapeutics announced June 19. The company said the approval came after a phase III trial showed that treatment in a laborato[...]
  • CLARIFICATION: Novel female sexual dysfunction drug effective, phase III studies show

    on June 21st, 2017
    In an article titled “Novel female sexual dysfunction drug effective, phase III studies show”, published June 19, 2017, the name of the company marketing Addyi and one of Dr. Clayton’s disclosures was misstated. The name of the company is Valeant.[...]
  • Brexanolone appears effective for severe postpartum depression

    on June 19th, 2017
    FROM THE LANCET A single 60-hour infusion of brexanolone dramatically and rapidly improves severe postpartum depression with minimal adverse effects, a small manufacturer-conducted phase II trial suggests. Brexanolone is a proprietary formulation of allopregnanolone, the major metabolite of progeste[...]
  • Teens’ overall tobacco use falls, but e-cigs now most popular product

    on June 19th, 2017
    FROM MMWR Twenty percent of surveyed high school students and 7% of middle school students were using some kind of tobacco product in 2016 – and e-cigarettes were the most commonly used product among those groups, according to an analysis from federal researchers. Current use of any tobacco produc[...]
  • Novel female sexual dysfunction drug effective, phase III studies show

    on June 19th, 2017
    AT THE ASCP ANNUAL MEETING MIAMI (FRONTLINE MEDICAL NEWS) – Women distressed by a low desire for sex could have a novel pharmaceutical intervention soon. Phase III results from the two Reconnect studies of 1,247 premenopausal women with hypoactive sexual desire disorder in stable relationships sho[...]
  • Daytime sleepiness linked to subsequent brain amyloid

    on June 16th, 2017
    AT SLEEP 2017 BOSTON (FRONTLINE MEDICAL NEWS) – Daytime sleepiness in cognitively intact older adults was significantly associated with subsequent neuroimaging evidence of brain amyloid deposition, according to a data analysis presented at the annual meeting of the Associated Professional Sleep So[...]
  • Most veterans with schizophrenia or bipolar I report suicide attempts

    on June 16th, 2017
    AT APA SAN DIEGO (FRONTLINE MEDICAL NEWS) – A new study reports that about half of assessed U.S. veterans with schizophrenia or bipolar I disorder have tried to kill themselves. Nearly 70% of those with schizophrenia had documented suicidal behavior or ideation, as did more than 82% of those with [...]
  • Tweaking CBT to boost outcomes in GAD

    on June 15th, 2017
    EXPERT ANALYSIS FROM THE ANXIETY AND DEPRESSION CONFERENCE 2017 SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – The search is on for ways to refine cognitive-behavioral therapy for generalized anxiety disorder in order to improve upon current relatively modest success rates. Cognitive-behavioral therapy [...]
  • Treatment response rates for psychotic bipolar depression similar to those without

    on June 15th, 2017
    AT THE ASCP ANNUAL MEETING MIAMI (FRONTLINE MEDICAL NEWS) – Response rates for psychotic and nonpsychotic depression in bipolar disorder were statistically similar, regardless of treatment, an ad hoc analysis has shown. Over a 6 month period, results from the multisite, randomized, controlled Bipo[...]
Back to top